October 8, 2021 08:33 AM EDT
Bioregnum

Care about R&D strate­gies? Have we got a sum­mit for you

If there’s one un­der­ly­ing les­son I’ve learned watch­ing bio­phar­ma in ac­tion over the past 20 years or so, it’s that no R&D or­ga­ni­za­tion can rest …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

For­mer Karuna crew quick­ly as­sem­bles $225M for next neu­ro bet at Sea­port

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

As­traZeneca-backed CD­MO Nu­cle­us Ra­dio­Phar­ma to boost com­mer­cial ca­pac­i­ty

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times